Breakthrough in oncology! 
The FDA has approved Lynozyfic(linvoseltamab) toward patients with relapsed/refractory multiple myeloma who’ve undergone at least four prior treatments—a bispecific antibody targeting CD3 and BCMA. This marks a major step ahead for precision cancer therapy. It can provide a renewed sense of hope and more targeted care for the patients. The future in oncology has arrived.
medboundhub #CancerInnovation
3 Likes
Informative.
1 Like
Great breakthrough! As it gives precise and target oriented action it will decrease the malignant cells.
1 Like
Very recently I read about it. Thank you so much for sharing. I think the FDA approval came around early July 2025. “Lynozyfic” helps in fighting against multiple myeloma by linking T-cells that carry CD3 directly with the cancer cells expressing BCMA. In 70 percentage of patients, this drug showed a positive response and it also exhibited lasting benefits. This durability is extremely significant especially for patients with relapsed conditions who have limited options.
1 Like
Informative.
1 Like
Intresting
1 Like
For patients battling multiple myeloma after years of exhausting options, this opens a much-needed new door. It’s a treatment that zeroes in with purpose, offering the possibility of better control and improved quality of life when few choices remain. Moments like this remind us how far cancer research has come and how much hope innovation can bring.
1 Like
Great news for people with multiple myeloma! Lynozyfic is a new medicine that works by targeting cancer cells more precisely. It’s for patients who have already tried many treatments. I feel this new option brings hope and better care for those fighting this cancer. A big step forward in cancer treatment!
1 Like
Great innovation, which can change the lives of cancer patients undergoing therapy.
1 Like
The approval of Lynozyfic signals more than just another treatment option it represents a shift toward truly personalised cancer care. By harnessing the precision of bispecific antibodies, oncology is moving closer to treatments that are both more effective and less toxic, offering renewed hope for patients facing the toughest battles.
1 Like
Great innovation and intresting
1 Like
Such an exciting milestone in cancer treatment! The approval of linvoseltamab offers new hope for multiple myeloma patients who have exhausted other options.
1 Like